Direxion Daily S&P Biotech Bull 3X ETF
LABU
14 hedge funds and large institutions have $23.2M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.3% less ownership
Funds ownership: 6.8% → 6.5% (-0.3%)
37% less call options, than puts
Call options by funds: $40.4M | Put options by funds: $64.1M
51% less capital inflows, than outflows
Capital inflows: $5.48M | Capital outflows: $11.2M
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
+$3.52M |
| 2 |
Morgan Stanley
New York
|
+$860K |
| 3 |
Traynor Capital Management
Malvern,
Pennsylvania
|
+$483K |
| 4 |
Citigroup
New York
|
+$96.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$82.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wolverine Asset Management
Chicago,
Illinois
|
-$5.59M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.22M |
| 3 |
HJMC
Hellman Jordan Management Company
Quincy,
Massachusetts
|
-$2.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$685K |
| 5 |
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
-$192K |
LABU Hedge Fund Activity: Q2 2018 in Review
14 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2018, worth a combined $23.2M — down 5.7% from $24.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LABU positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $3.52M. The largest seller was Wolverine Asset Management, cutting an estimated $5.59M.
- 14 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2018, up from 13 in Q1 2018.
- Funds reported $23.2M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2018, down 5.7% quarter-over-quarter.
- 5 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2018 and 4 closed out, a net change of +1 holder.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2018 was Tower Research Capital (TRC), an estimated $3.52M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2018 was Wolverine Asset Management, an estimated $5.59M sold.
Based on aggregated 13F filings for Q2 2018.